title: Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
abstract: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved for the treatment of advanced renal cell carcinoma, imatinib-refractory gastrointestinal stromal tumor, and advanced pancreatic neuroendocrine tumors. The current studies were conducted to characterize the pharmacokinetics, distribution, and metabolism of sunitinib after intravenous and/or oral administrations of [(14)C]sunitinib in rats (5 mg/kg i.v., 15 mg/kg p.o.), monkeys (6 mg/kg p.o.), and humans (50 mg p.o.). After oral administration, plasma concentration of sunitinib and total radioactivity peaked from 3 to 8 h. Plasma terminal elimination half-lives of sunitinib were 8 h in rats, 17 h in monkeys, and 51 h in humans. The majority of radioactivity was excreted to the feces with a smaller fraction of radioactivity excreted to urine in all three species. The bioavailability in female rats was close to 100%, suggesting complete absorption of sunitinib. Whole-body autoradioluminography suggested radioactivity was distributed throughout rat tissues, with the majority of radioactivity cleared within 72 h. Radioactivity was eliminated more slowly from pigmented tissues. Sunitinib was extensively metabolized in all species. Many metabolites were detected both in urine and fecal extracts. The main metabolic pathways were N-de-ethylation and hydroxylation of indolylidene/dimethylpyrrole. N-Oxidation/hydroxylation/desaturation/deamination of N,N'-diethylamine and oxidative defluorination were the minor metabolic pathways. Des-ethyl metabolite M1 was the major circulating metabolite in all three species.
authors.affiliation: Pharmacokinetics, Dynamics & Metabolism, Sandwich, Kent, United Kingdom.
authors.forename: Bill
authors.initials: B
authors.lastname: Speed
authors.forename: Hai-Zhi
authors.initials: HZ
authors.lastname: Bu
authors.forename: William F
authors.initials: WF
authors.lastname: Pool
authors.forename: Geoffrey W
authors.initials: GW
authors.lastname: Peng
authors.forename: Ellen Y
authors.initials: EY
authors.lastname: Wu
authors.forename: Shem
authors.initials: S
authors.lastname: Patyna
authors.forename: Carlo
authors.initials: C
authors.lastname: Bello
authors.forename: Ping
authors.initials: P
authors.lastname: Kang
mesh_terms: D000042:Absorption / Q000502:physiology; D000284:Administration, Oral; D000328:Adult; D000818:Animals; D001682:Biological Availability; D002247:Carbon Isotopes / Q000008:administration & dosage / Q000378:metabolism / Q000652:urine; D002250:Carbon Radioisotopes; D005243:Feces / Q000737:chemistry; D005260:Female; D006207:Half-Life; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics* / Q000652:urine; D007275:Injections, Intravenous / Q000379:methods; D008252:Macaca fascicularis; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics* / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077210:Sunitinib; D014018:Tissue Distribution; D055815:Young Adult
chemical_list: D002247:Carbon Isotopes; D002250:Carbon Radioisotopes; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib